Amgen Inc
NASDAQ:AMGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amgen Inc
NASDAQ:AMGN
|
US |
|
Essential Properties Realty Trust Inc
F:2OU
|
US |
|
N
|
Novo Nordisk A/S
XMUN:NOVA
|
DK |
|
N
|
Novo Nordisk A/S
XMUN:NOV
|
DK |
Intrinsic Value
Is AMGN undervalued or overvalued?
See the intrinsic value estimate for Amgen Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
AMGN looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with AMGN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Amgen Does
Amgen is a biotechnology company that discovers, develops, manufactures, and sells prescription medicines for serious diseases. Its drugs focus on areas such as cancer, bone health, inflammation, heart disease, and rare conditions. The company’s main customers are doctors, hospitals, specialty pharmacies, and health systems that prescribe or dispense these treatments to patients.
- Headquarters
- United States of America US
- Employees
- 31 500
- IPO date
- Jun 17, 1983
Amgen has a wide economic moat
Patents and exclusive rights to sell approved medicines prevent rivals from freely copying important Amgen treatments. These protections span a broad range of medicines, allowing Amgen to defend profits across several diseases rather than depend on a single drug.
Read the full moat analysis
Revenue & Expenses Breakdown
Amgen Inc
Earnings Waterfall
Amgen Inc
The intrinsic value for Amgen Inc (AMGN) under the Base Case is hidden USD.
Compared with the current market price of 442.7 USD, the stock appears hidden.